ArticleCancer discovery2023

The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.

Patricia LoRusso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.